Policy & Regulation
Zealand Pharma announces return of worldwide rights to Amylin analog programme from Boehringer Ingelheim
23 March 2020 -

Zealand Pharma A/S (Zealand) (CPH:ZEAL), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced on Friday the return by Boehringer Ingelheim of an Amylin analog that was being developed for the treatment of obesity and Type 2 diabetes.

Reportedly, the Amylin analog programme was licensed to Boehringer Ingelheim in 2014 to conduct and finance all clinical development and commercialisation, with Zealand eligible to receive milestone payments and royalties on global sales.

As of 20 March 2020, this license agreement will no longer be active. The long-term partnership will continue with the license agreement to develop the GLP-1/glucagon analog BI 456906, which is planned to advance into phase 2 development.

Zealand added that it will communicate the potential of further development of the Amylin programme at a later stage, following a thorough evaluation.